Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade

Study (n=396) found probability of treatment failure was 27% at 3 years after single agent anti–PD-1 (pembrolizumab or nivolumab) treatment discontinuation; and response was seen in 5/34 patients retreated with single-agent anti–PD-1.

Journal of Clinical Oncology